Japan Myocardial Infarction Market Size, Share & Trends Analysis Report by Type (ST-Elevation Myocardial Infarction (STEMI), Non-ST Elevation Myocardial Infarction (NSTEMI), and Silent Heart Attacks), by Device (Left Ventricular Assist Device, Pacemaker, Catheter, Implantable Cardioverter Defibrillator, and Others), by Diagnosis (Electrocardiography (ECG), Chest X-Ray, Computed Tomography (CT Scan), Echocardiography, and Others), by Treatment (Medication and Surgery), and by End-Users (Hospitals & Clinics, Ambulatory Surgical Centers, and Research Institutes) and Forecast, 2020-2026.
Japan myocardial infarction market is estimated to grow modestly at a CAGR of around 7.0% during the forecast period. The growth of the myocardial infarction market in Japan is being supported by innovative and advanced product launches by the key regional market players. The geriatric population is one of the major concerns for the Japanese government and other healthcare institutions in the country. As per the UN, out of the total 126 million population, about 27% population of the country was above 65 years in 2019. The possibility of a heart attack in the geriatric population is relatively high as compared to the young population. As per the Institute for Health Metrics and Evaluation, the country is witnessing a modest growth in the cases related to CVD. In 2014, 3.40 million new cases of CVD were witnessed in the country which was slightly increased to 3.54 million in 2017.
The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.
The companies which are contributing to the growth of the Japan myocardial infarction market include AstraZeneca PLC, Bayer AG, Abbott Laboratories Inc., GlaxoSmithKline PLC, Pfizer Inc., Koninklijke Philips N.V., Medtronic PLC, and Merck KGaA. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Research Methodology
The market study of the Japan myocardial infarction market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation
1. Japan Myocardial Infarction Market Research and Analysis by Type
2. Japan Myocardial Infarction Market Research and Analysis by Device
3. Japan Myocardial Infarction Market Research and Analysis by Diagnosis
4. Japan Myocardial Infarction Market Research and Analysis by Treatment
5. Japan Myocardial Infarction Market Research and Analysis by End-Users
The Report Covers
Japan myocardial infarction market is estimated to grow modestly at a CAGR of around 7.0% during the forecast period. The growth of the myocardial infarction market in Japan is being supported by innovative and advanced product launches by the key regional market players. The geriatric population is one of the major concerns for the Japanese government and other healthcare institutions in the country. As per the UN, out of the total 126 million population, about 27% population of the country was above 65 years in 2019. The possibility of a heart attack in the geriatric population is relatively high as compared to the young population. As per the Institute for Health Metrics and Evaluation, the country is witnessing a modest growth in the cases related to CVD. In 2014, 3.40 million new cases of CVD were witnessed in the country which was slightly increased to 3.54 million in 2017.
The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.
The companies which are contributing to the growth of the Japan myocardial infarction market include AstraZeneca PLC, Bayer AG, Abbott Laboratories Inc., GlaxoSmithKline PLC, Pfizer Inc., Koninklijke Philips N.V., Medtronic PLC, and Merck KGaA. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Research Methodology
The market study of the Japan myocardial infarction market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation
1. Japan Myocardial Infarction Market Research and Analysis by Type
2. Japan Myocardial Infarction Market Research and Analysis by Device
3. Japan Myocardial Infarction Market Research and Analysis by Diagnosis
4. Japan Myocardial Infarction Market Research and Analysis by Treatment
5. Japan Myocardial Infarction Market Research and Analysis by End-Users
The Report Covers
- Comprehensive research methodology of the Japan myocardial infarction market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Japan myocardial infarction market.
- Insights about market determinants which are stimulating the Japan myocardial infarction market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Company Profiles
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories Inc.
- AstraZeneca PLC
- Bayer AG
- Boston Scientific Corp.
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- Medtronic PLC
- Merck KGaA
- Mylan N.V.
- Novartis AG
- Pfizer Inc.
- Siemens AG